SMMT实时信号 | 通过Getagraph.com最大化利润

购买 123217 min ago

@ $4.41

发出时间: 15 Feb 2024 @ 04:08

回报率: 8.39%

上一信号: Feb 15 - 03:15

上一信号: 出售

回报率: -0.23 %

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 04:00):

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America...

Stats
今日成交量	2.08M
平均成交量	2.28M
市值	3.36B
EPS	$0 ( 2024-05-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	12.58
ATR14	$0.0110 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Ronaghi Mostafa	Buy	25 315	Stock Option (right to buy)
2024-04-11	Ronaghi Mostafa	Buy	200 000	Stock Option (right to buy)
2024-04-11	Ronaghi Mostafa	Buy	0
2024-04-02	Soni Manmeet Singh	Buy	1 100 000	Stock Option (right to buy)
2024-04-02	Anand Bhaskar	Buy	600 000	Stock Option (right to buy)

INSIDER POWER
99.42
Last 89 transactions
Buy: 581 405 260 \| Sell: 937 995

音量相关性

長: -0.41 (neutral)

短: -0.89 (strong negative)

Signal:(41.982) Neutral

Summit Therapeutics plc 相关性

10 最正相关
ACST	0.898
TATT	0.892
NPCE	0.892
DRTT	0.89
VSTM	0.884
AVIR	0.881
GLMD	0.881
MREO	0.879
CNXC	0.872
SRPT	0.87

10 最负相关
MTEK	-0.922
BFRI	-0.905
CINC	-0.873
SNCR	-0.868
MLVF	-0.862
SLDP	-0.858
LEDS	-0.858
PPBT	-0.858
XPDI	-0.856
PMD	-0.852

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Summit Therapeutics plc 相关性 - 货币/商品

0.24
( neutral )

0.27
( neutral )

0.00
( neutral )

-0.38
( neutral )

-0.77
( moderate negative )

-0.07
( neutral )

Summit Therapeutics plc 财务报表

Annual	2023
营收:	$0
毛利润:	$-2.05M (0.00 %)
EPS:	$-0.990

FY	2023
营收:	$0
毛利润:	$-2.05M (0.00 %)
EPS:	$-0.990

FY	2022
营收:	$704 295
毛利润:	$-1.81M (-256.95 %)
EPS:	$-0.380

FY	2021
营收:	$1 809.00
毛利润:	$1 809.00 (100.00 %)
EPS:	$-0.000960

Financial Reports:

No articles found.

Summit Therapeutics plc

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.